Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis
BACKGROUND: Circulating IgA anti-citrullinated protein antibodies (ACPA) associate with more active disease, but a previous study implied that salivary IgA ACPA is related to a less severe disease. Therefore, we aimed to characterize the IgA ACPA response in the saliva and serum in relation to clinical picture and risk factors among patients with rheumatoid arthritis (RA).
METHODS: RA patients (n = 196) and healthy blood donors (n = 101), included in the cross-sectional study "Secretory ACPA in Rheumatoid Arthritis" (SARA), were analyzed for ACPA of IgA isotype, and for subclasses IgA1 and IgA2 ACPA in paired saliva and serum samples using modified enzyme-linked immunosorbent assays (ELISA) targeting reactivity to a cyclic citrullinated peptide (anti-CCP). Cutoff levels for positive tests were set at the 99th percentile for blood donors. Antibody levels were related to clinical characteristics, radiographic damage, smoking habits, and carriage of HLA-DRB1/shared epitope (SE).
RESULTS: IgA ACPA in the saliva was found in 12% of RA patients, IgA1 occurred in 10%, and IgA2 in 9%. In serum, IgA ACPA was found in 45% of the patients, IgA1 in 44%, and IgA2 in 39%. Levels of IgA ACPA in the saliva correlated significantly with serum levels of IgA (r = 0.455). The presence of salivary IgA ACPA was associated with a higher erythrocyte sedimentation rate (ESR), 28-joint disease activity score, tender joint count, and patient global assessment at the time of sampling. None of the antibodies was associated with smoking, SE, or radiographic damage.
CONCLUSION: Salivary IgA ACPAs were detected in a subset of RA patients in association with higher disease activity. This suggests that mucosal ACPA responses in the oral cavity may contribute to disease-promoting processes in RA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Arthritis research & therapy - 22(2020), 1 vom: 23. Nov., Seite 274 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Roos Ljungberg, Karin [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.05.2021 Date Revised 28.05.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s13075-020-02363-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317929801 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317929801 | ||
003 | DE-627 | ||
005 | 20231225164307.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13075-020-02363-0 |2 doi | |
028 | 5 | 2 | |a pubmed24n1059.xml |
035 | |a (DE-627)NLM317929801 | ||
035 | |a (NLM)33225988 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Roos Ljungberg, Karin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.05.2021 | ||
500 | |a Date Revised 28.05.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Circulating IgA anti-citrullinated protein antibodies (ACPA) associate with more active disease, but a previous study implied that salivary IgA ACPA is related to a less severe disease. Therefore, we aimed to characterize the IgA ACPA response in the saliva and serum in relation to clinical picture and risk factors among patients with rheumatoid arthritis (RA) | ||
520 | |a METHODS: RA patients (n = 196) and healthy blood donors (n = 101), included in the cross-sectional study "Secretory ACPA in Rheumatoid Arthritis" (SARA), were analyzed for ACPA of IgA isotype, and for subclasses IgA1 and IgA2 ACPA in paired saliva and serum samples using modified enzyme-linked immunosorbent assays (ELISA) targeting reactivity to a cyclic citrullinated peptide (anti-CCP). Cutoff levels for positive tests were set at the 99th percentile for blood donors. Antibody levels were related to clinical characteristics, radiographic damage, smoking habits, and carriage of HLA-DRB1/shared epitope (SE) | ||
520 | |a RESULTS: IgA ACPA in the saliva was found in 12% of RA patients, IgA1 occurred in 10%, and IgA2 in 9%. In serum, IgA ACPA was found in 45% of the patients, IgA1 in 44%, and IgA2 in 39%. Levels of IgA ACPA in the saliva correlated significantly with serum levels of IgA (r = 0.455). The presence of salivary IgA ACPA was associated with a higher erythrocyte sedimentation rate (ESR), 28-joint disease activity score, tender joint count, and patient global assessment at the time of sampling. None of the antibodies was associated with smoking, SE, or radiographic damage | ||
520 | |a CONCLUSION: Salivary IgA ACPAs were detected in a subset of RA patients in association with higher disease activity. This suggests that mucosal ACPA responses in the oral cavity may contribute to disease-promoting processes in RA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Anti-citrullinated protein antibodies (ACPA) | |
650 | 4 | |a IgA subclasses | |
650 | 4 | |a Immunoglobulin A (IgA) | |
650 | 4 | |a Mucosal immunity | |
650 | 4 | |a Rheumatoid arthritis | |
650 | 4 | |a Saliva | |
650 | 7 | |a Anti-Citrullinated Protein Antibodies |2 NLM | |
650 | 7 | |a Autoantibodies |2 NLM | |
650 | 7 | |a Immunoglobulin A |2 NLM | |
650 | 7 | |a Peptides, Cyclic |2 NLM | |
700 | 1 | |a Börjesson, Emil |e verfasserin |4 aut | |
700 | 1 | |a Martinsson, Klara |e verfasserin |4 aut | |
700 | 1 | |a Wetterö, Jonas |e verfasserin |4 aut | |
700 | 1 | |a Kastbom, Alf |e verfasserin |4 aut | |
700 | 1 | |a Svärd, Anna |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Arthritis research & therapy |d 2003 |g 22(2020), 1 vom: 23. Nov., Seite 274 |w (DE-627)NLM124870457 |x 1478-6362 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2020 |g number:1 |g day:23 |g month:11 |g pages:274 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-020-02363-0 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2020 |e 1 |b 23 |c 11 |h 274 |